Analyzing Tevogen Bio (NASDAQ:TVGN) and Qiagen (NYSE:QGEN)

Qiagen (NYSE:QGEN) and Tevogen Bio (NASDAQ:TVGN) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, institutional ownership and analyst recommendations.

Risk and Volatility

Qiagen has a beta of 0.36, suggesting that its stock price is 64% less volatile than the S&P 500. Comparatively, Tevogen Bio has a beta of -1.14, suggesting that its stock price is 214% less volatile than the S&P 500.

Profitability

This table compares Qiagen and Tevogen Bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Qiagen	4.23%	13.92%	8.40%
Tevogen Bio	N/A	-396.07%	749.97%

Valuation & Earnings

This table compares Qiagen and Tevogen Bio”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qiagen	$1.98 billion	4.24	$83.59 million	$0.36	105.14
Tevogen Bio	N/A	N/A	-$70,000.00	N/A	N/A

Qiagen has higher revenue and earnings than Tevogen Bio.

Institutional and Insider Ownership

70.0% of Qiagen shares are owned by institutional investors. 9.0% of Qiagen shares are owned by insiders. Comparatively, 56.6% of Tevogen Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Qiagen and Tevogen Bio, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qiagen	0	7	3	0	2.30
Tevogen Bio	0	0	2	0	3.00

Qiagen presently has a consensus price target of $47.71, indicating a potential upside of 26.05%. Tevogen Bio has a consensus price target of $7.10, indicating a potential upside of 459.06%. Given Tevogen Bio’s stronger consensus rating and higher probable upside, analysts clearly believe Tevogen Bio is more favorable than Qiagen.

Summary

Qiagen beats Tevogen Bio on 7 of the 11 factors compared between the two stocks.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.

About Tevogen Bio

Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.